Jazz Pharmaceuticals

company

About

Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments.

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$6.99M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2003
Number Of Employee
501 - 1000
Operating Status
Active
Stock Symbol
nasdaq:JAZZ
Legal Name
Jazz Pharmaceuticals, Inc.
Also Known As
Jazz Pharmaceuticals plc

Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. Jazz Pharmaceuticals focuses on identifying, developing, and commercializing products for neurology and psychiatry primarily in the United States. Its products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Cystadane for the treatment of homocystinuria, an inherited metabolic disease; and Antizol to treat ethylene glycol and methanol poisoning. Its late-stage product candidates comprise Luvox CR, an extended-release formulation of fluvoxamine, a selective serotonin reuptake inhibitor, which is used for the treatment of obsessive-compulsive disorder and social anxiety disorder; and JZP-6, a liquid dosage form of sodium oxybate in Xyrem, for the treatment of fibromyalgia syndrome.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
7
$2.06B
Jazz Pharmaceuticals has raised a total of $2.06B in funding over 2 rounds. Their latest funding was raised on Apr 22, 2021 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 22, 2021 Post-IPO Debt $1.50B Detail
Dec 7, 2009 Post-IPO Debt $120M Detail
Jul 8, 2009 Post-IPO Equity $6.99M 1 Longitude Capital Detail
May 8, 2008 Post-IPO Equity $75M 1 Detail
May 31, 2007 IPO $108M Detail

Investments

Number of Investments
Number of Lead Investments
6
3
Jazz Pharmaceuticals has made 6 investments. Their most recent investment was on Dec 31, 2021, when Casa raised $21M.
Date Company Name
Round Money Raised Industry Lead Investor
Dec 31, 2021 Casa
Series A $21M Bitcoin
Jul 29, 2021 Onera Health
Series B €10.50M Health Diagnostics
Jul 29, 2021 Onera Health
Series B €10.50M Health Care
Apr 24, 2019 Onera Health
Series A €8.16M Health Care Yes
Apr 23, 2019 Onera Health
Series A $9.30M Health Diagnostics Yes

Employee Profiles

Number of Employee Profiles
22
Jazz Pharmaceuticals has 22 current employee profiles, including Board member Elmar Schnee
Board member
Board member
Employee
Executive

Acquisition

Jazz Pharmaceuticals has acquired 9 organizations. Their most recent acquisition was Orphan Medical on Apr 19, 2005. They acquired Orphan Medical for $122.60M.

Date Company Name
Industry Acquisition Type Price
Apr 19, 2005 Orphan Medical
Health Care acquisition $ 122.60M Detail
Sep 19, 2011 Azur Pharma
Biotechnology acquisition Detail
Apr 26, 2012 EUSA Pharma
Biotechnology $ 650M Detail
Dec 19, 2013 Gentium
Biotechnology Detail
May 11, 2016 Amolyt Pharma
Biotechnology acquisition $ 20.50M Detail